CAROL KIMANI: Open Payments
NPI 1366153827 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 33 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $668 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 3 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $149 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $148 |
| Phathom Pharmaceuticals, Inc. | 1 | $121 |
| ABBVIE INC. | 4 | $95 |
| Lilly USA, LLC | 3 | $82 |
| Janssen Biotech, Inc. | 3 | $77 |
| PFIZER INC. | 4 | $77 |
| GENZYME CORPORATION | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
Products named: REZDIFFRA, XIFAXAN, ENTYVIO, VOQUEZNA, OMVOH, TREMFYA, VELSIPITY, RINVOQ.
Industry payments across MD — which companies pay providers there.
